Inflectra: adverse event reports filed with FDA

25,300

reports as suspect product

0.1% of all reports · about 2,283 a year

863

reports, 12 months to June 2026

3,169 in the 12 months before

83.4%

marked serious by the reporter

56.2% across the class

2.5%

record death among outcomes, as reported

623 reports · not verified by FDA

Reports by month, five years

Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

By year received

2026 covers reports received through June 2026 only.

Reactions recorded in the reports

share of Inflectra reports recording the termmedian drug in tumor necrosis factor blocker

1. Off label useused for a purpose or in a way not on the label57.1%14,446
2. Condition aggravatedthe condition being treated got worse41.3%10,447
3. Intentional product use issuedeliberate use not as intended32.2%8,158
4. Inappropriate schedule of product administrationthe product was taken at the wrong times23.9%6,041
5. Arthralgiajoint pain18.3%4,639
6. Fatiguetiredness12.3%3,106
7. Drug ineffectivethe medicine did not work as expected12.2%3,094
8. Weight increasedweight gain11.3%2,860
9. Malaisegeneral feeling of being unwell10.8%2,731
10. Weight decreasedweight loss10.7%2,715
11. Blood pressure increaseda raised blood pressure reading9.2%2,333
12. Covid-19COVID-19 infection8.9%2,252
13. Headachehead pain8.7%2,205
14. Nauseafeeling sick8.5%2,141
15. Painpain, site not specified8.2%2,072
16. Blood pressure fluctuation7.7%1,939
17. Therapeutic response shortened7.2%1,832
18. Nasopharyngitisa cold7.2%1,817
19. Coughcough7%1,762
20. Pyrexiafever6.3%1,589
21. Heart rate decreased6.1%1,552
22. Incorrect dose administeredthe wrong dose was given5.9%1,503
23. Pruritusitching5.5%1,385
24. Dizzinesslight-headedness or unsteadiness5.4%1,369
25. Dyspnoeashortness of breath5.2%1,321
26. Abdominal painstomach or belly pain5.1%1,289
27. Drug level decreaseda low blood level of the medicine4.8%1,225
28. Diarrhoealoose or frequent stools4.8%1,209
29. Vomitingbeing sick4.7%1,194
30. Drug level below therapeutic4.6%1,170

Top 30 of 2,400 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 17 drugs in the tumor necrosis factor blocker class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Outcomes recorded

Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 1,064,042 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."

Patients and reporters

Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 20% of reports give the United States as the country of the event or reporter.

Reason for use recorded

The indication field is filled in by the reporter and is often blank; shares are of all 25,300 reports.

Drugs most often listed in the same reports

Other products listed in reports where Inflectra is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.

In context

Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Other drugs in the tumor necrosis factor blocker class

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Inflectra as a suspect or interacting product; reports listing it only as a concomitant medication (1,344) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.